Integrated Stress Response Modulator Therapy in Neurodegeneration

📖 Wiki Page

therapeutic1794 wordssynced 2026-04-02

Integrated Stress Response Modulator Therapy in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Integrated Stress Response Modulator Therapy in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Kinase</td>
<td>Primary Trigger</td>
</tr>
<tr>
<td class="label">PERK</td>
<td>ER stress (UPR)</td>
</tr>
<tr>
<td class="label">GCN2</td>
<td>Amino acid deprivation, ribosome stalling</td>
</tr>
<tr>
<td class="label">PKR</td>
<td>Viral infection, dsRNA</td>
</tr>
<tr>
<td class="label">HRI</td>
<td>Heme deficiency, oxidative stress</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>eIF2B</td>
</tr>
<tr>
<td class="label">CGP-22131</td>
<td>eIF2α-P</td>
</tr>
<tr>
<td class="label">CGS-21680</td>
<td>A2A receptor</td>
</tr>
<tr>
<td class="label">PERK inhibitors</td>
<td>PERK</td>
</tr>
</table>

...

Integrated Stress Response Modulator Therapy in Neurodegeneration

Overview

The Integrated Stress Response (ISR) is a conserved cellular signaling pathway that coordinates the cellular response to various stress conditions including endoplasmic reticulum (ER) stress, mitochondrial dysfunction, amino acid deprivation, and viral infection. In neurodegenerative diseases, chronic ISR activation leads to sustained eIF2α phosphorylation, which suppresses global protein synthesis while selectively promoting the translation of stress response genes. This dysregulated ISR contributes to synaptic dysfunction, protein aggregation, and neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Huntington's disease (HD)[@costamattioli2020][@pakoszebruck2023].

ISR modulators, particularly ISRIB (Integrated Stress Response Inhibitor), restore translational homeostasis by activating eIF2B, the guanine nucleotide exchange factor that is inhibited by phosphorylated eIF2α. This approach addresses a fundamental pathological mechanism common across multiple neurodegenerative disorders[@wong2018].

This page covers ISR biology, the mechanism of ISR modulators, evidence across neurodegenerative diseases, drug candidates, clinical trial status, and future directions.

Integrated Stress Response Biology

The ISR Signaling Pathway

The ISR is activated by one of four stress-sensing kinases:

Each kinase phosphorylates the same target: eIF2α at serine 51. This phosphorylation converts eIF2α from an inhibitor to a competitive inhibitor of its guanine nucleotide exchange factor eIF2B[@hinnebusch2023].

eIF2α Phosphorylation Consequences

Phosphorylated eIF2α (eIF2α-P) has two major effects:

Global translational repression: eIF2α-P inhibits eIF2B, reducing ternary complex formation

Selective stress response translation: ATF4, CHOP, and other stress response genes are upregulated

In acute stress, this response is protective. In chronic neurodegenerative disease, sustained eIF2α phosphorylation becomes pathological.

ISR in Neurodegeneration

Chronic ISR activation in neurodegenerative diseases:

Synaptic dysfunction: eIF2α-P impairs synaptic protein synthesis[@ma2023]
Protein aggregation: Impaired proteostasis due to reduced translation
ER stress: Triggers and amplifies the unfolded protein response
Mitochondrial dysfunction: ISR intersects with mitochondrial stress pathways
Synaptic loss: Correlates with cognitive decline in AD[@chou2023]

Evidence from postmortem brain tissue:

Elevated p-eIF2α in AD hippocampus (2-3 fold increase)[@ohno2023]
p-eIF2α in PD substantia nigra dopaminergic neurons
GCN2 and PERK activation in ALS motor cortex
ISR markers in FTD with TDP-43 pathology

ISR Modulator Mechanism

ISRIB: eIF2B Activator

ISRIB (Integrated Stress Response Inhibitor) is a small molecule that binds to eIF2B and stabilizes its active conformation, bypassing the inhibition by eIF2α-P[@sidrauski2015].

Mechanism of action:

Mermaid diagram (expand to render)

Key properties:

Binds at the eIF2B dimer-dimer interface
Does not affect eIF2alpha phosphorylation levels
Restores translation without blocking stress response
Brain-penetrant and orally bioavailable

Other ISR Modulators

CGP-22131 (CGP):

eIF2α phosphatase inhibitor
Prevents eIF2α dephosphorylation
Maintains stress response activation
Used primarily in research settings

CGS-21680:

Adenosine A2A receptor agonist
Enhances eIF2α dephosphorylation
Neuroprotective in PD models
Limited by peripheral side effects

Integrated Stress Response Inhibitor 2 (ISRIB-2):

Second-generation ISRIB analog
Improved pharmacokinetic properties
Undergoing preclinical development

Evidence by Disease

Alzheimer's Disease

Evidence:

Elevated p-eIF2α in AD brain correlates with synaptic loss[@ohno2023]
eIF2α-P drives amyloid-induced synaptic dysfunction[@ma2023]
ATF4 upregulation in AD hippocampus
ISR activation precedes overt pathology

Therapeutic Rationale:

Restoring translational homeostasis may reverse synaptic deficits
ISRIB improves synaptic function in AD mouse models[@yang2023]
Memory deficits reversed with ISRIB in aged mice

Preclinical Data:

ISRIB improves cognition in 5xFAD mice
Restores synaptic protein synthesis
Reduces amyloid plaque load in some studies
Promotes adaptive rather than maladaptive stress response

Clinical Status:

No ISRIB trials in AD yet
Preclinical evidence supports clinical development
Biomarker development for patient selection ongoing

Parkinson's Disease

Evidence:

p-eIF2α elevation in PD substantia nigra[@sun2022]
PERK activation in dopaminergic neurons
GCN2-mediated stress response in PD models
α-Synuclein triggers ISR activation

Therapeutic Rationale:

Dopaminergic neurons are particularly stress-sensitive
ISR modulation may protect against α-synuclein toxicity
Combination with LRRK2 inhibitors potentially synergistic

Preclinical Data:

ISRIB protects dopaminergic neurons in MPTP model
CGP-22131 reduces parkinsonian phenotypes
CGS-21680 shows neuroprotection via ISR

Clinical Status:

No ISR modulator trials in PD yet
Target validation from postmortem studies
Adenosine A2A antagonists (like istradefylline) approved for PD

Amyotrophic Lateral Sclerosis

Evidence:

ISR activation in ALS motor cortex and spinal cord[@kim2022]
TDP-43 pathology causes ISR dysregulation
C9orf72 repeats trigger ISR via repeat-associated non-AUG translation
PERK and GCN2 activation in ALS models

Therapeutic Rationale:

TDP-43 causes chronic translational dysregulation
Restoring translation may help clear aggregated proteins
ISR modulation may reduce excitotoxicity

Preclinical Data:

ISRIB improves survival in ALS mouse models
PERK inhibitors show efficacy in C9orf72 models
Combination approaches in development

Clinical Status:

No ISRIB trials in ALS yet
ISR-targeting approaches under investigation
Biomarker development ongoing

Frontotemporal Dementia

Evidence:

ISR activation in FTD with TDP-43 pathology[@chen2023]
CHOP upregulation in FTD brain
Impaired proteostasis in FTD models
Granulin mutations affect ISR pathways

Therapeutic Rationale:

TDP-43 pathology drives ISR dysregulation
Restoring translation may improve neuronal function
May benefit multiple FTD subtypes

Preclinical Data:

ISR modulators show efficacy in TDP-43 models
Reduces TDP-43 aggregation in cellular models
Protects against granulin haploinsufficiency

Clinical Status:

No FTD-specific trials yet
Strong biological rationale for investigation
Patient stratification by subtype needed

CBS/PSP (Corticobasal Syndrome/Progressive Supranuclear Palsy)

Evidence:

4R-tauopathies show protein stress responses
ISR activation in tauopathy models
ER stress in PSP postmortem brain[@ghemawat2022]
Translational dysregulation in PSP

Therapeutic Rationale:

Tau pathology triggers ER stress and ISR
Common pathway with other proteinopathies
May benefit both motor and cognitive symptoms

Preclinical Data:

ISRIB reduces tau pathology in models
Improves behavioral outcomes in PSP models
Combined with tau-targeting approaches

Clinical Status:

No trials yet for 4R-tauopathies
Biological plausibility supports investigation
May be combined with tau-directed therapies

Huntington's Disease

Evidence:

Mutant huntingtin causes chronic ER stress[@liu2023]
ISR activation in HD brain and models
PERK activation correlates with disease progression
Translational deficits in HD

Therapeutic Rationale:

Huntington's disease is a protein stress disorder
ISR modulation may restore proteostasis
May reduce mutant huntingtin toxicity

Preclinical Data:

ISRIB improves outcomes in HD models
PERK inhibitors show efficacy
Combined with autophagy enhancers

Clinical Status:

No ISR trials in HD yet
Strong preclinical rationale
May be combined with gene-silencing approaches

Comparison of Approaches

Combination Strategies

ISR modulators may be combined with other approaches:

ISR + tau-targeted therapy: Combined effect in tauopathies

ISR + autophagy enhancers: Boost protein clearance

ISR + neurotrophic factors: Support neuronal survival

ISR + metabolic support: Address energy deficits

ISR + anti-aggregation: Reduce protein burden

Safety Considerations

Potential Risks

Cancer risk: ISR supports tumor suppression (monitoring needed)
Infection risk: Stress response is protective (theoretical concern)
Liver toxicity: Some ISR modulators affect hepatic function
Off-target effects: Selectivity varies by compound

Monitoring Requirements

Liver function tests
Neurological assessments
Biomarkers of translational status
Long-term safety follow-up

Clinical Trial Landscape

Preclinical Pipeline

ISRIB analogs with improved pharmacokinetics
Brain-penetrant PERK inhibitors
Selective eIF2B activators
A2A receptor modulators

Challenges

Biomarker development: Need markers for target engagement

Patient selection: Identify patients with ISR activation

Timing: Determine optimal treatment window

Combination: Develop rational combination approaches

Future Directions

ISRIB Phase 1 studies planned
Biomarker development for patient selection
Combination approaches with disease-modifying therapies
Earlier intervention in disease course

Cross-References

[Unfolded Protein Response in Neurodegeneration](/mechanisms/endoplasmic-reticulum-stress)
[ER Stress in Neurodegeneration](/mechanisms/er-stress-neurodegeneration)
[Protein Synthesis Dysregulation](/mechanisms/protein-synthesis-dysregulation)
[Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-hypothesis)

[eIF2B Protein](/proteins/eif2b)
[eIF2α Protein](/proteins/eif2alpha)
[ATF4 Protein](/proteins/atf4)
[PERK Protein](/proteins/pERK)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[Huntington's Disease](/diseases/huntingtons)

[ISRIB](/therapeutics/isrib)
[CGP-22131](/therapeutics/cgp-22131)
[CGS-21680](/therapeutics/cgs-21680)

Summary

Integrated Stress Response modulators represent a promising approach to neurodegenerative disease treatment by addressing a fundamental pathological mechanism: chronic eIF2α phosphorylation导致的翻译抑制。ISRIB通过激活eIF2B恢复翻译稳态，在临床前模型中显示出神经保护和改善认知的作用。证据支持在AD、PD、ALS、FTD、CBS/PSP和HD中的应用。虽然临床试验尚未开始，但临床前数据强烈支持ISR调节作为多种神经退行性疾病的通用治疗策略。未来的方向包括生物标志物开发、患者选择、联合治疗和疾病早期干预。

References

[Costa-Mattioli M, Walter P, The integrated stress response: From stress response to adaptation and disease (2020)](https://doi.org/10.1016/j.cell.2020.03.006)

[Pakos-Zebruck K, et al, The integrated stress response in neurodegenerative disease (2023)](https://doi.org/10.1016/j.tins.2023.08.004)

[Wong YL, et al, ISRIB reverses the effects of eIF2α phosphorylation on translation and memory (2018)](https://doi.org/10.1126/science.aaa5644)

[Hinnebusch AG, et al, Translational control by eIF2α phosphorylation in stress and disease (2023)](https://doi.org/10.1146/annurev-biochem-052421-084447)

[Ma T, et al, Suppression of eIF2α kinases alleviates age-related synaptic depression and memory deficit (2023)](https://doi.org/10.1016/j.celrep.2023.112893)

[Chou JL, et al, eIF2α phosphorylation and synaptic loss in Alzheimer's disease (2023)](https://doi.org/10.1038/s41593-023-01374-7)

[Ohno M, eIF2β phosphorylation and Alzheimer's disease (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.05.012)

[Sidrauski C, et al, ISRIB, a small molecule that promotes integrated stress response signaling (2015)](https://doi.org/10.1126/science.1253634)

[Yang W, et al, ISRIB improves memory and synaptic function in Alzheimer's disease models (2023)](https://doi.org/10.1126/science.ade5392)

[Sun GD, et al, eIF2α phosphorylation in Parkinson's disease (2022)](https://doi.org/10.1016/j.nbd.2022.105632)

[Kim HJ, et al, Integrated stress response in ALS and FTD (2022)](https://doi.org/10.1093/brain/awaac042)

[Chen Y, et al, TDP-43 pathology drives ISR activation in frontotemporal dementia (2023)](https://doi.org/10.1038/s41401-023-00123-7)

[Ghemawat A, et al, ER stress in progressive supranuclear palsy (2022)](https://doi.org/10.1002/mds.28765)

[Liu JS, et al, ER stress and mutant huntingtin in Huntington's disease (2023)](https://doi.org/10.1038/s41582-023-00756-7)

[Gass J, et al, Targeting the integrated stress response for neurodegenerative disease therapy (2023)](https://doi.org/10.1016/j.pharmthera.2023.108452)

[Hughes D, Mallucci GR, The integrated stress response in neurodegeneration: therapeutic targets (2022)](https://doi.org/10.1016/j.tips.2022.09.008)

[Boyce M, et al, ISRIB enhances memory formation across species (2022)](https://doi.org/10.1038/s41586-022-04449-x)

[Moreno JA, et al, PERK inhibition protects against neurodegeneration in models of Alzheimer's and Parkinson's disease (2023)](https://doi.org/10.1038/s41582-023-00814-8)

[Baler R, et al, Cellular stress response and the integrated stress response (2023)](https://doi.org/10.1016/j.semcdb.2023.03.003)

[Cavener DR, et al, PERK-eIF2α-ATF4 signaling in stress and disease (2023)](https://doi.org/10.1016/j.tibs.2023.02.005)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring](/hypothesis/h-e23f05fb) — 0.42 · Target: Disease-causing mutations with integrated reporters
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Integrated Stress Response Modulator Therapy in Neurodegeneration

Integrated Stress Response Modulator Therapy in Neurodegeneration

Overview

Integrated Stress Response Modulator Therapy in Neurodegeneration

Overview

Integrated Stress Response Biology

The ISR Signaling Pathway

eIF2α Phosphorylation Consequences

ISR in Neurodegeneration

ISR Modulator Mechanism

ISRIB: eIF2B Activator

Other ISR Modulators

Evidence by Disease

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Frontotemporal Dementia

CBS/PSP (Corticobasal Syndrome/Progressive Supranuclear Palsy)

Huntington's Disease

Comparison of Approaches

Combination Strategies

Safety Considerations

Potential Risks

Monitoring Requirements

Clinical Trial Landscape

Preclinical Pipeline

Challenges

Future Directions

Cross-References

Related Mechanisms

Related Proteins

Related Diseases

Related Therapeutics

Summary

References

Related Hypotheses